SPNT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Buy SPNT now. The chart is turning up (positive/expanding MACD, neutral-not-overbought RSI), price is sitting close to a defined support/pivot zone (~20.01), options positioning is aggressively call-skewed, and the latest company news (redeeming the high-cost Series B preferred) is a clean, near-term balance-sheet/earnings-quality catalyst ahead of the Feb 17 earnings print. While Wall Street’s lone recent initiation is only Market Perform (suggesting near-term valuation/insurance-cycle risks), the overall setup favors an immediate entry for an impatient buyer.
Trend/Setup: Mildly bullish. MACD histogram is positive (0.0544) and expanding, suggesting upside momentum is building. RSI(6) at 57.9 is neutral (not overbought), leaving room for continuation. Moving averages are converging, consistent with a potential inflection/transition from consolidation to trend. Levels: Pivot 20.006 is the key “line in the sand.” Current price 20.41 is just above pivot, which is a favorable location for an impatient entry. Near resistance levels: R1 20.683 then R2 21.10; a push through R1 would strengthen the breakout case. Supports: S1 19.33 then S2 18.913. Pattern-based forward look (provided): Similar-pattern stats imply small drift near-term (next day/week), but a stronger 1-month tendency (+7.92%), aligning with a swing-friendly backdrop into earnings.
Intellectia Proprietary Trading Signals
• 2026-01-29: Redemption of all Series B 8% preferred shares (removes ongoing preferred dividend burden/capital cost, improves leverage flexibility).
• Earnings catalyst ahead: QDEC 2025 earnings on 2026-02-17 (after hours) can act as a sentiment/price catalyst.
• Operational/financial momentum: Latest reported quarter shows sharp YoY improvement in profitability (supports “quality of earnings” narrative).
• Options market positioning is heavily call-skewed, often supportive of near-term upside.
• Analyst (Raymond James) frames valuation as already reflecting much of the restructuring progress after strong 2025 outperformance—limits near-term multiple expansion.
• Industry risk: catastrophe losses and weaker pricing environment could pressure underwriting margins and growth.
• Elevated implied volatility suggests the market is pricing a large move; if earnings/news disappoint, the downside reaction can be sharp.
• No notable insider/hedge-fund accumulation trends cited recently (neutral sentiment from sophisticated holders).
Latest quarter: 2025/Q3. • Revenue: $753.8M, +10.82% YoY (solid top-line growth). • Net income: $86.7M, +1870.45% YoY (major profitability inflection). • EPS: $0.73, +2333.33% YoY (earnings power improving rapidly). Overall: Clear YoY acceleration in earnings and EPS, consistent with a post-restructuring improvement cycle and supportive of buying on a near-support chart setup.
Recent trend: Limited coverage update—on 2026-01-16, Raymond James initiated at Market Perform. Pros (Wall St. view): Multiyear restructuring improved earnings quality, reduced volatility, and enhanced underwriting profitability; target 12–15% ROE through the cycle. Cons (Wall St. view): Much of the improvement appears priced in after strong 2025 performance; near-term headwinds from catastrophe risk and weaker pricing could cap growth and margin expansion. Net: Cautiously balanced Street stance, but not outright negative; the market is effectively requiring continued execution to justify further upside.
